Incyte Corp (INCY) Financial Statements
Industry: Commercial Physical & Biological Research (Services)
In fiscal 2025, Incyte reported revenue of $5.14B, up 21.2% from $4.24B the year before. Net income was $1.29B (a 25.0% net margin), or $6.41 per diluted share. Gross margin was 92.8% and operating margin was 29.5%. Operating activities generated $1.41B of cash, leaving $1.36B of free cash flow. At fiscal year end, Incyte held $6.96B in total assets against $1.79B in total liabilities, including $3.10B of cash and equivalents.
Open the full interactive Incyte financials → Quarterly statements, key ratios, valuation history and price charts.
Incyte Key Stats
| Share Price | $108.62 |
|---|---|
| Market Cap | $22.62B |
| P/E Ratio | 16.9 |
| Revenue YoY Growth | +21.2% |
| 52-Week Range | $84.73 – $129.93 |
| Shares Outstanding | 200.4 million (basic, 2026 Q2) |
Incyte Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.67B | $2.99B | $3.39B | $3.70B | $4.24B | $5.14B |
| Cost of Goods Sold | $2.93B | $2.40B | $2.82B | $3.08B | $4.18B | $3.63B |
| Gross Profit | $2.54B | $2.84B | $3.19B | $3.44B | $3.93B | $4.77B |
| Operating Income | -$263.7M | $585.8M | $579.4M | $620.5M | $61.4M | $1.51B |
| Pre-Tax Income | -$232.2M | $570.4M | $529.1M | $834.2M | $316.6M | $1.66B |
| Income Tax | $63.5M | -$378.1M | $188.5M | $236.6M | $284.0M | $377.8M |
| Net Income | -$295.7M | $948.6M | $340.7M | $597.6M | $32.6M | $1.29B |
| Diluted EPS | -$1.36 | $4.27 | $1.52 | $2.65 | $0.15 | $6.41 |
Incyte Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.37B | $1.51B | $1.27B | $1.67B |
| Net Income | $424.2M | $299.3M | $303.3M | $585.6M |
| Diluted EPS | $2.11 | $1.49 | $1.47 | $2.81 |
Incyte Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.51B | $2.06B | $2.95B | $3.21B | $1.69B | $3.10B |
| Current Assets | $2.36B | $3.12B | $4.09B | $4.65B | $3.24B | $5.02B |
| Total Assets | $3.56B | $4.93B | $5.84B | $6.78B | $5.44B | $6.96B |
| Current Liabilities | $631.2M | $854.3M | $1.16B | $1.24B | $1.64B | $1.52B |
| Total Liabilities | $949.6M | $1.16B | $1.47B | $1.59B | $2.00B | $1.79B |
| Shareholders' Equity | $2.61B | $3.77B | $4.37B | $5.19B | $3.45B | $5.17B |
Incyte Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$124.6M | $749.5M | $969.9M | $496.5M | $335.3M | $1.41B |
| Cash From Investing | -$269.0M | -$207.7M | -$78.5M | -$207.7M | $157.5M | -$102.6M |
| Cash From Financing | $71.7M | $6.2M | -$794,000 | -$20.0M | -$2.02B | $101.0M |
| Free Cash Flow | -$312.0M | $568.5M | $892.1M | — | $286.6M | $1.36B |
Figures from Incyte's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Incyte financials page for every line item.
Incyte Company Profile
| Ticker | INCY |
|---|---|
| Exchange | Nasdaq |
| Industry | Commercial Physical & Biological Research (Services) |
| Headquarters | Wilmington, Delaware |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000879169 |
Frequently Asked Questions
What was Incyte's revenue in fiscal 2025?
Incyte (INCY) reported revenue of $5.14B for fiscal 2025.
What is Incyte's annual revenue history?
Incyte's annual revenue by fiscal year: 2020: $2.67B; 2021: $2.99B; 2022: $3.39B; 2023: $3.70B; 2024: $4.24B; 2025: $5.14B.
What was Incyte's net income in fiscal 2025?
Incyte reported net income of $1.29B for fiscal 2025.
What was Incyte's earnings per share (EPS) in fiscal 2025?
Incyte's diluted EPS was $6.41 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Incyte generate in fiscal 2025?
Incyte generated $1.36B of free cash flow in fiscal 2025.
What was Incyte's revenue last quarter?
In its most recent reported quarter (2026 Q2), Incyte reported revenue of $1.67B.
How many shares of Incyte are outstanding?
Incyte reported a weighted average of 200.4 million basic shares outstanding in 2026 Q2.
What is Incyte's market cap?
Based on its latest closing price, Incyte (INCY) has a market capitalization of about $22.62B.
When does Incyte's fiscal year end?
Incyte's fiscal year end, as registered with the SEC, is December 31.
Where is Incyte headquartered?
Incyte lists its business address in Wilmington, Delaware in its SEC filings.
Incyte Competitors & Similar Companies
See all 12 Commercial Physical & Biological Research (Services) companies →